Last reviewed · How we verify
Botulinum toxin A 12.5U
At a glance
| Generic name | Botulinum toxin A 12.5U |
|---|---|
| Sponsor | YangHui |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers (PHASE1)
- Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid (PHASE3)
- Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases (PHASE2, PHASE3)
- Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm (NA)
- Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin A 12.5U CI brief — competitive landscape report
- Botulinum toxin A 12.5U updates RSS · CI watch RSS
- YangHui portfolio CI